Abstract
Immunotherapy is already an integral part of the treatment of metastatic non-small cell lung cancer (NSCLC). The results of a number of studies have shown an increase in overall survival time in higher treatment lines, and we now have the results of clinical trials that have demonstrated the benefit of immunotherapy in combination with chemotherapy in the first line, regardless of PD-L1 expression (programmed cell death receptor ligand 1).
In Phase III IMpower150 trial, the benefit of the combination of atezolizumab, bevacizumab and chemotherapy was evaluated in patients with previously untreated non-squamous metastatic NSCLC. Based on the results of the evaluation, the combination of atezolizumab, bevacizumab, paclitaxel and carboplatin was approved by the US Food and Drug Administration (FDA) in December 2018 and the European Medicines Agency (EMA) in March 2019 in the first-line treatment of metastatic non-squamous NSCLC including patients with EGFR mutation or alteration of the ALK gene after failure of targeted therapy.